PCI Synthesis, a pharmaceutical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, is changing its name to SEQENS. 

The name change comes six months after PCI Synthesis was acquired by Novacap. The new corporate entity, SEQENs, also combines PCAS, Uetikon and Proteus. 

The move positions SEQENS as an integrated global leader in pharmaceutical synthesis and specialty ingredients, delivering outstanding performance, unrivaled market responsiveness and tailor-made solutions to its customers. By consolidating its service offerings, SEQENS can better serve its customers with global access to its 3,200 employees, including more than 300 scientists, engineers and experts, and ensure that products are successfully transferred into production. 

The name change is effective today but the company will roll out the new name at its Newburyport and Devens locations and on its website. By the end of Q1 2019,  signage and websites will be updated to reflect the new corporate entity. Ed Price, founder of PCI Synthesis, and his management team, remain with the company. SEQENS remains committed to PCI Synthesis’ employees – and maintaining staffing plans that call for more hires – and to its facilities in Newburyport and Devens; the company will continue to invest in training and equipment to solve its sponsors’ analytical and drug substance development and manufacturing needs.